Vectus Biosystems Narrows Loss But Net Tangible Assets Turn Negative

The latest announcement is out from Vectus Biosystems Limited ( (AU:VBS) ).

Vectus Biosystems reported a sharp decline in income from ordinary activities for the half year ended 31 December 2025, with revenue falling 99% to just $5,488. The company also posted a net loss attributable to members of $731,694, a 33% improvement on the prior corresponding period, and confirmed that no interim or final dividends were declared.

The company’s balance sheet weakened, with net tangible assets per ordinary share dropping from 0.76 cents at 31 December 2024 to negative 1.51 cents at 31 December 2025, underscoring ongoing capital strain. The half-year financial statements were reviewed by the company’s auditors, and the report was approved by the board, signaling continued regulatory compliance despite the challenging financial metrics.

The most recent analyst rating on (AU:VBS) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Vectus Biosystems Limited stock, see the AU:VBS Stock Forecast page.

More about Vectus Biosystems Limited

Vectus Biosystems Limited is an Australian biotechnology company focused on developing medical technologies, operating in the broader life sciences sector. It is listed on the ASX and remains in a pre-revenue or early-revenue phase, with its financial performance driven largely by research and development activities rather than commercial product sales.

Average Trading Volume: 70,762

Technical Sentiment Signal: Hold

Current Market Cap: A$7.48M

For a thorough assessment of VBS stock, go to TipRanks’ Stock Analysis page.